These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 19573605)

  • 1. The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants.
    Secchi M; Xu Q; Lusso P; Vangelista L
    Protein Expr Purif; 2009 Nov; 68(1):34-41. PubMed ID: 19573605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of Lactobacillus jensenii to secrete RANTES and a CCR5 antagonist analogue as live HIV-1 blockers.
    Vangelista L; Secchi M; Liu X; Bachi A; Jia L; Xu Q; Lusso P
    Antimicrob Agents Chemother; 2010 Jul; 54(7):2994-3001. PubMed ID: 20479208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.
    Blanpain C; Doranz BJ; Bondue A; Govaerts C; De Leener A; Vassart G; Doms RW; Proudfoot A; Parmentier M
    J Biol Chem; 2003 Feb; 278(7):5179-87. PubMed ID: 12466283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5.
    Kish-Catalone TM; Lu W; Gallo RC; DeVico AL
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1497-509. PubMed ID: 16569870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.
    Mack M; Luckow B; Nelson PJ; Cihak J; Simmons G; Clapham PR; Signoret N; Marsh M; Stangassinger M; Borlat F; Wells TN; Schlöndorff D; Proudfoot AE
    J Exp Med; 1998 Apr; 187(8):1215-24. PubMed ID: 9547333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of the HIV-1 inhibitory activity of RANTES by modification of the N-terminal region: dissociation from CCR5 activation.
    Polo S; Nardese V; De Santis C; Arcelloni C; Paroni R; Sironi F; Verani A; Rizzi M; Bolognesi M; Lusso P
    Eur J Immunol; 2000 Nov; 30(11):3190-8. PubMed ID: 11093134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Highly potent, fully recombinant anti-HIV chemokines: reengineering a low-cost microbicide.
    Gaertner H; Cerini F; Escola JM; Kuenzi G; Melotti A; Offord R; Rossitto-Borlat I; Nedellec R; Salkowitz J; Gorochov G; Mosier D; Hartley O
    Proc Natl Acad Sci U S A; 2008 Nov; 105(46):17706-11. PubMed ID: 19004761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus type 1 entry inhibitors selected on living cells from a library of phage chemokines.
    Hartley O; Dorgham K; Perez-Bercoff D; Cerini F; Heimann A; Gaertner H; Offord RE; Pancino G; Debré P; Gorochov G
    J Virol; 2003 Jun; 77(12):6637-44. PubMed ID: 12767983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.
    Kawamura T; Bruse SE; Abraha A; Sugaya M; Hartley O; Offord RE; Arts EJ; Zimmerman PA; Blauvelt A
    J Virol; 2004 Jul; 78(14):7602-9. PubMed ID: 15220435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of anti-HIV-1 activity by hot spot evolution of RANTES-derived peptides.
    Secchi M; Longhi R; Vassena L; Sironi F; Grzesiek S; Lusso P; Vangelista L
    Chem Biol; 2012 Dec; 19(12):1579-88. PubMed ID: 23261601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral chemokines: intracellular life of recombinant C-C chemokine RANTES.
    Owais M; Arya SK
    J Hum Virol; 1999; 2(5):270-82. PubMed ID: 10551733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
    Hartley O; Gaertner H; Wilken J; Thompson D; Fish R; Ramos A; Pastore C; Dufour B; Cerini F; Melotti A; Heveker N; Picard L; Alizon M; Mosier D; Kent S; Offord R
    Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16460-5. PubMed ID: 15545608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs.
    Torre VS; Marozsan AJ; Albright JL; Collins KR; Hartley O; Offord RE; Quiñones-Mateu ME; Arts EJ
    J Virol; 2000 May; 74(10):4868-76. PubMed ID: 10775626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and functional studies of the potent anti-HIV chemokine variant P2-RANTES.
    Jin H; Kagiampakis I; Li P; Liwang PJ
    Proteins; 2010 Feb; 78(2):295-308. PubMed ID: 19722264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells.
    Longden J; Cooke EL; Hill SJ
    Br J Pharmacol; 2008 Apr; 153(7):1513-27. PubMed ID: 18223665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. O-GalNAcylation of RANTES Improves Its Properties as a Human Immunodeficiency Virus Type 1 Entry Inhibitor.
    Guan X; Chaffey PK; Chen H; Feng W; Wei X; Yang LM; Ruan Y; Wang X; Li Y; Barosh KB; Tran AH; Zhu J; Liang W; Zheng YT; Wang X; Tan Z
    Biochemistry; 2018 Jan; 57(1):136-148. PubMed ID: 29202246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semisynthetic analogues of PSC-RANTES, a potent anti-HIV protein.
    Gaertner H; Offord R; Botti P; Kuenzi G; Hartley O
    Bioconjug Chem; 2008 Feb; 19(2):480-9. PubMed ID: 18179159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.
    Marozsan AJ; Torre VS; Johnson M; Ball SC; Cross JV; Templeton DJ; Quiñones-Mateu ME; Offord RE; Arts EJ
    J Virol; 2001 Sep; 75(18):8624-38. PubMed ID: 11507208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of -2 RANTES vaginal microbicide formulations in a nonhuman primate simian/human immunodeficiency virus (SHIV) challenge model.
    Kish-Catalone T; Pal R; Parrish J; Rose N; Hocker L; Hudacik L; Reitz M; Gallo R; Devico A
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):33-42. PubMed ID: 17263630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.